Lannett Starts Trial For Lantus Rival With HEC
Lannett has announced the start of an initial clinical trial in South Africa for the insulin glargine biosimilar it is developing with HEC for the US market.
You may also be interested in...
Lannett’s Phase I trial for biosimilar insulin glargine has met “all primary endpoints,” the company has announced. The rival to Sanofi’s Lantus is being developed by Lannett with partner HEC through a deal for which financial details have just been revealed.
Having failed to find a buyer for its raw materials business in Cody, US, Lannett now intends to shut down the operation.
US firm Lannett, which recently lost a key distribution deal involving a highly profitable thyroid drug, raised its sales guidance for fiscal 2019 and was upbeat on its prospects after reporting third-quarter net profit that fell by 17% to $10.6m.